Niklas Carlén Appointed Interim CEO of Stille AB
Torbjörn Sköld will begin his tenure as new Stille’s new CEO on March 20th, 2023, where he will replace Hanna Ernestam Wilkman who has been the company’s CEO since April 1st, 2019. Stille’s board of directors have decided to appoint Niklas Carlén as Interim CEO up until Torbjörn will commence his employment. Niklas has been the company’s CFO since June 2020.
Torshälla, January 25th, 2023.
This information is such information that Stille AB is obliged to disclose according to the EU’s market abuse regulation. The information was, through the agency of the contact person, rendered for publication on January 25th, 2023, kl. 15.50 (CET).
For more information, please contact:
Chairman of the Board
+46 (0)70 512 00 21 | [email protected]
Stille AB (publ) publ) develops, manufactures and markets medical devices for surgeons across the world. Stille was founded in 1841 and is one of the world’s oldest medical device companies. Stille’s main business areas are surgical instruments and c-arm tables. Stille’s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures. the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality. The share is listed on First North Growth Market under the acronym “STIL” with Eminova AB as Certified Adviser, Eminova Fondkommission AB, + 46 8 684 211 10, [email protected] For more information, visit www.stille.se.
InDex Pharmaceuticals updates the timeline of the phase III study CONCLUDE with cobitolimod
January 27, 2023 – InDex Pharmaceuticals Holding AB (publ) today announced an update in the timing of the dose selection in the ongoing phase III study CONCLUDE with the drug candidate cobitolimod. The outcome of the dose selection is expected to be available Q4 2023. At that point in time InDex wil...
InDex Pharmaceuticals uppdaterar tidplanen för fas III-studien CONCLUDE med cobitolimod
27 januari, 2023 – InDex Pharmaceuticals Holding AB (publ) meddelar idag en uppdatering av tidplanen för valet av dos i den pågående fas III-studien CONCLUDE med läkemedelskandidaten cobitolimod. Utfallet av dosvalet förväntas fjärde kvartalet 2023. Vid den tidpunkten har InDex slutfört bedömning av...
Mentice’s CEO Göran Malmberg to present the company’s Year-end Report Q4 2022 at a earnings call on February 3rd at 10:00 CET
The presentation of the Year-end Report Q4 for the period October – December 2022 will be held on February 3rd, 2023, at 10:00 CET. The live broadcast is followed by a Q&A moderated by Redeye’s analyst Christian Binder. For more information on how to register, please visit https://investor.menti...